These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14411872)

  • 1. The determination of antigenic potency of poliomyelitis vaccine by measuring its antibody-combining capacity.
    KRECH U
    Bull World Health Organ; 1960; 22(3-4):307-11. PubMed ID: 14411872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing-antibody-combining (NAC) test for measuring antigenic potency of poliomyelitis vaccine.
    BENYESH-MELNICK M; MELNICK JL
    Bull World Health Organ; 1959; 20(6):1075-98. PubMed ID: 13799058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic potency of poliomyelitis vaccine; influence on degree and duration of vaccine effect.
    SALK JE
    J Am Med Assoc; 1956 Dec; 162(16):1451-9. PubMed ID: 13376316
    [No Abstract]   [Full Text] [Related]  

  • 4. [Determination of the antigenic value of poliomyelitis vaccine].
    DE SOMER P; PRINZIE A; DE MAEYER E; LAMY M
    Bull World Health Organ; 1960; 22(3-4):295-305. PubMed ID: 13815062
    [No Abstract]   [Full Text] [Related]  

  • 5. [On the in vitro titration of the antigenic power of vaccines against poliomyelitis].
    PETRILLI FL; AGNESE G; CROVARI P
    Boll Ist Sieroter Milan; 1960; 39():168-88. PubMed ID: 14432312
    [No Abstract]   [Full Text] [Related]  

  • 6. Potency of poliomyelitis vaccines estimated by an antibody combining test.
    CRAWFORD JG; FIELD MF
    J Bacteriol; 1960 Jul; 80(1):111-8. PubMed ID: 13812712
    [No Abstract]   [Full Text] [Related]  

  • 7. [Examinations on poliomyelitis antibodies in the population and the practical significance of antibody determination in poliomyelitis vaccination].
    KELLER W
    Monatsschr Kinderheilkd (1902); 1956 Mar; 104(3):135-6. PubMed ID: 13321825
    [No Abstract]   [Full Text] [Related]  

  • 8. [Control of the antigenic power of vaccine for poliomyelitis prepared with inactivated virus].
    CASTELLI L; BALDUCCI D; MANCINI G; PAULUZZI S
    Riv Ist Sieroter Ital; 1960; 35():529-38. PubMed ID: 13691408
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody responses to British poliomyelitis vaccine of children with naturally occurring antibody.
    RUSSELL K
    Br Med J; 1958 Mar; 1(5071):622-4. PubMed ID: 13510748
    [No Abstract]   [Full Text] [Related]  

  • 10. SAFETY and antigenic potency testing of poliomyelitis vaccine; a report from the Biological Standards Control Laboratory, Medical Research Council Laboratories, London, N.W.3.
    Br Med J; 1957 Jul; 2(5037):124-6. PubMed ID: 13436874
    [No Abstract]   [Full Text] [Related]  

  • 11. A method for the rapid determination of immunogenic potency of poliomyelitis vaccines by single vaccination of white rats.
    GHENDON IZ; MARCHENKO AT
    Acta Virol; 1959 Oct; 3():250-2. PubMed ID: 13849934
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistence of antibody in children after a third dose of poliomyelitis vaccine and their response to a fourth.
    LOGAN JS; FIELD AM; MACRAE AD; MILLER A; TOBIN JO
    Br Med J; 1960 Jun; 1(5187):1692-4. PubMed ID: 14417964
    [No Abstract]   [Full Text] [Related]  

  • 13. Further observations on the persistence of antibody in adolescents after a third dose of killed poliomyelitis vaccine.
    KENDALL EJ; MILLER A; TOBIN JO
    Br Med J; 1961 Jan; 1(5220):176-7. PubMed ID: 13752460
    [No Abstract]   [Full Text] [Related]  

  • 14. An international collaborative study of the assay of the potency of poliomyelitis sera.
    BENTZON MW; EVANS DG; MAALOE O; PERKINS FT; SPAUN J
    Bull World Health Organ; 1962; 26(3):341-55. PubMed ID: 13867397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)].
    ENDERS-RUCKLE G; SIEGERT R
    Dtsch Med Wochenschr; 1961 Oct; 86():1999-2008. PubMed ID: 13890174
    [No Abstract]   [Full Text] [Related]  

  • 16. Production of formalinized poliomyelitis vaccine (Salk-type) on a semi-industrial scale.
    GOLDBLUM N; GOTLIEB T; MILLER G
    Bull World Health Organ; 1957; 17(6):1001-23. PubMed ID: 13511145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay of poliomyelitis neutralizing antibody in disposable plastic panels.
    MELNICK JL; OPTON EM
    Bull World Health Organ; 1956; 14(1):129-46. PubMed ID: 13329842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The formation of neutralizing antibodies in humans after poliomyelitis immunization with the Behring vaccine].
    KELLER W; SAUTHOFF R
    Dtsch Med Wochenschr; 1955 Sep; 80(37):1329-31. PubMed ID: 13261706
    [No Abstract]   [Full Text] [Related]  

  • 19. [Study of poliomyelitis antibodies in Lorraine before, during and after vaccination with the Lepine vaccine in a group of subjects observed systematically].
    de LAVERGNE ; GERBAUT P; LORRAIN J; POLJE F; GILGENKRANTZ ; LE MOYNE MT; MATHIEU J
    Ann Inst Pasteur (Paris); 1959 Dec; 97():848-54. PubMed ID: 14414644
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody response and survival following booster injections of poliomyelitis (killed-virus) vaccine.
    BATSON R; CHRISTIE A; CHEATHAM WJ; MICHAL ML; SLEIGHT GW
    Pediatrics; 1962 Jan; 29():116-20. PubMed ID: 13865768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.